Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
vertical-expand: a:0:{}
caf_enhance: 0
Drug Category: Array
Conference Category: Array
Lead Author: J Foley, et al.
Published Date: 18/09/2024
Download Link: /wp-content/uploads/2024/09/P1516-TG-Octave-Poster-ECTRIMS-2024_FINAL.pdf
Download Text:
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top